Physician profile
David I Bruce
NPI 1740250505
$7,277.54
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $784 · 2021: $1,470 · 2022: $1,561 · 2023: $1,893 · 2024: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149 · Entertainment: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.87 |
| Entertainment | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,051.80 | 2019-2023 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $878.76 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $764.15 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $508.16 | 2019-2024 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.50 | 2019-2024 | Jardiance |
| Abbott Laboratories | $356.89 | 2019-2023 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $318.11 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $294.55 | 2019-2024 | |
| Amgen INC. | $285.02 | 2019-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $231.58 | 2021-2024 | Viberzi, Linzess, Qulipta |
| Merck Sharp & Dohme LLC | $219.65 | 2019-2023 | Belsomra, Gardasil 9, Pneumovax 23 |
| Sanofi-Aventis U.S. LLC | $184.69 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $163.30 | 2021-2023 | Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $138.12 | 2021-2023 | |
| Radius Health, INC. | $122.11 | 2019-2021 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.